3 ms·

> I'm actually surprised how close Canada's vaccination rate is to the US - 35% vs 45%. The comparison is deceptive, since most of those 45% of Americans have

> I'm actually surprised how close Canada's vaccination rate is to the US - 35% vs 45%. The comparison is deceptive, since most of those 45% of Americans have finished two doses (apparently 32% as of May 4 [1]) while very few of the Canadians have (3% [2]). In other words, we've put a fair bit less than half as many shots in arms per person. [1] https://www.npr.org/sections/health-shots/2021/01/28/960901166/how-is-the-covid-19-vaccination-campaign-going-in-your-state https://www.npr.org/sections/health-shots/2021/01/28/9609011... [2] https://www.npr.org/sections/health-shots/2021/01/28/960901166/how-is-the-covid-19-vaccination-campaign-going-in-your-state https://www.npr.org/sections/health-shots/2021/01/28/9609011...

arcticbull 5y ago
Yes, however, there's no evidence that's less effective in the near term, and there's mounting evidence that spreading out the second dose is as effective - or more so. [1] So I guess it depends on what you're trying to measure. tl;dr: is that spreading out the dosage of Moderna vaccine to 9-15 weeks actually makes it a more effective vaccine. Spreading out Pfizer, more relevant to Canada, also reduces the number of hospitalizations and deaths over the recommended schedule. [1] [1] https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001211 https://journals.plos.org/plosbiology/article?id=10.1371/jou...
- refurb 5y ago
  Your reference is a modeling exercise and says nothing about vaccine effectiveness in an individual.
  - deleted 5y ago
    [deleted]
  - arcticbull 5y ago
    There's individual data, too. [1] There's a lot of data coming out about this and it's pretty much a trade-off. You get more people some level of immunity, reducing spread, and you improve the quality of the immunity with a delayed dose vs. immediate turn. The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose. There's a lot of work going on now to study this, and the results coming out are all pointing at this being a pretty good path forward. [1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
- stormbrew 5y ago
  I mean sure, that might all be true (I'm pretty hesitant to buy it but it's not like my opinion matters, they're doing it regardless), but you said you were surprised at it and this is why it looks that way. Either way, though, the US is either considerably or extremely ahead of us still.

arcticbull 5y ago

Yes, however, there's no evidence that's less effective in the near term, and there's mounting evidence that spreading out the second dose is as effective - or more so. [1] So I guess it depends on what you're trying to measure. tl;dr: is that spreading out the dosage of Moderna vaccine to 9-15 weeks actually makes it a more effective vaccine. Spreading out Pfizer, more relevant to Canada, also reduces the number of hospitalizations and deaths over the recommended schedule. [1] [1] https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001211 https://journals.plos.org/plosbiology/article?id=10.1371/jou...

refurb 5y ago
Your reference is a modeling exercise and says nothing about vaccine effectiveness in an individual.
- deleted 5y ago
  [deleted]
- arcticbull 5y ago
  There's individual data, too. [1] There's a lot of data coming out about this and it's pretty much a trade-off. You get more people some level of immunity, reducing spread, and you improve the quality of the immunity with a delayed dose vs. immediate turn. The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose. There's a lot of work going on now to study this, and the results coming out are all pointing at this being a pretty good path forward. [1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
stormbrew 5y ago
I mean sure, that might all be true (I'm pretty hesitant to buy it but it's not like my opinion matters, they're doing it regardless), but you said you were surprised at it and this is why it looks that way. Either way, though, the US is either considerably or extremely ahead of us still.